Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

26 Jul 2017

Abstract excerpt

gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to PARP inhibition in cancer therapy
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28747513
DOI: 10.1126/scitranslmed.aal1645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibitionPMID 28747513Read ↗

BET proteins regulate homologous recombination‐mediated DNA repair: BRCAness and implications for cancer therapySemantic proximity Read ↗

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity Read ↗

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsSemantic proximity Read ↗

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional MachinerySemantic proximity Read ↗

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cellsSemantic proximity Read ↗

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.Semantic proximity Read ↗

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceSemantic proximity Read ↗

BRD4 and Cancer: going beyond transcriptional regulationSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

The Functions of BET Proteins in Gene Transcription of Biology and DiseasesSemantic proximity Read ↗

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencySemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.